Published by Josh White on 18th April 2023
(Sharecast News) - Hutchmed China announced on Tuesday that its new drug application (NDA) for fruquintinib, in combination with paclitaxel has been accepted for review by the National Medical Products Administration (NMPA) in China.
URL: http://www.digitallook.com/dl/news/story/33442194/...